{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:29Z","timestamp":1791925409267,"version":"4.3.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"DOI":"10.5665\/sleep.4068","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T19:59:56Z","timestamp":1412107196000},"page":"1609-1619","source":"Crossref","is-referenced-by-count":44,"title":["Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects"],"prefix":"10.1093","volume":"37","author":[{"given":"Junshui","family":"Ma","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Whitehouse Station, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Svetnik","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Whitehouse Station, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Snyder","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Whitehouse Station, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Whitehouse Station, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roth","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital Sleep Center, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joseph","family":"Herring","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Whitehouse Station, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"key\n\t\t\t\t2018112203580424800_B1","first-page":"1049","article-title":"NIH statement regarding the treatment of insomnia. state of the science conference statement: manifestations and management of chronic insomnia in adults","volume":"28","author":"National Institutes of Health","year":"2005","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s13311-012-0148-3","article-title":"Insomnia pharmacotherapy","volume":"9","author":"Roehrs","year":"2012","journal-title":"Neurotherapeutics"},{"key":"key\n\t\t\t\t2018112203580424800_B3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11940-009-0039-z","article-title":"Treatment of sleep dysfunction and psychiatric disorders","volume":"11","author":"Becker","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"key\n\t\t\t\t2018112203580424800_B4","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1517\/14656566.2012.699523","article-title":"Off-label uses of trazodone: a review","volume":"13","author":"Bossini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2018112203580424800_B5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-444-59489-1.00010-0","article-title":"Orexin receptors as therapeutic drug targets","volume":"198","author":"Gotter","year":"2012","journal-title":"Prog Brain Res"},{"key":"key\n\t\t\t\t2018112203580424800_B6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","article-title":"The orexin system: roles in sleep\/wake regulation","volume":"1200","author":"Sakurai","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t2018112203580424800_B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(99)00955-6","article-title":"Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system","volume":"279","author":"Taheri","year":"2000","journal-title":"Neurosci Lett"},{"key":"key\n\t\t\t\t2018112203580424800_B8","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1523\/JNEUROSCI.23-08-03555.2003","article-title":"Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness","volume":"23","author":"Zeitzer","year":"2003","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t2018112203580424800_B9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2018112203580424800_B10","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2018112203580424800_B11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet"},{"key":"key\n\t\t\t\t2018112203580424800_B12","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2018112203580424800_B14","first-page":"97","article-title":"Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the first of two 3-month pivotal phase 3 trials","volume":"21","author":"Connor","year":"2012","journal-title":"J Sleep Res"},{"key":"key\n\t\t\t\t2018112203580424800_B15","first-page":"351","article-title":"Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the second of two 3-month pivotal phase 3 trials","volume":"21","author":"Ivgy-May","year":"2012","journal-title":"J Sleep Res"},{"key":"key\n\t\t\t\t2018112203580424800_B16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant, an orexin receptor antagonist, during 1-year treatment of insomnia followed by abrupt discontinuation of treatment: a randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurology"},{"key":"key\n\t\t\t\t2018112203580424800_B17","article-title":"The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications","author":"Iber","year":"2007"},{"key":"key\n\t\t\t\t2018112203580424800_B18","article-title":"A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects","author":"Rechtschaffen","year":"1968"},{"key":"key\n\t\t\t\t2018112203580424800_B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-0327(95)00033-J","article-title":"Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone","volume":"35","author":"Van Bemmel","year":"1995","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t2018112203580424800_B20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/npp.2011.310","article-title":"Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia","volume":"37","author":"Bettica","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t2018112203580424800_B21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0269881111424457","article-title":"EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia","volume":"26","author":"Lundahl","year":"2012","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t2018112203580424800_B22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/sleep\/30.5.593","article-title":"The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia","volume":"30","author":"Walsh","year":"2007","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.5665\/sleep.1996","article-title":"The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia","volume":"35","author":"Bettica","year":"2012","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2018112203580424800_B25","first-page":"1359","article-title":"Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies","volume":"31","author":"Lankford","year":"2008","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5664\/jcsm.27707","article-title":"Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies","volume":"6","author":"Roth","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"key\n\t\t\t\t2018112203580424800_B27","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/sleep\/33.11.1562","article-title":"Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem","volume":"33","author":"Svetnik","year":"2010","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.5664\/JCSM.1316","article-title":"EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women","volume":"7","author":"Ma","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"key\n\t\t\t\t2018112203580424800_B29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1109\/TAU.1967.1161901","article-title":"The use of fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms","volume":"15","author":"Welch","year":"1967","journal-title":"IEEE Trans Audio Electroacoustics"},{"key":"key\n\t\t\t\t2018112203580424800_B30","first-page":"189","article-title":"Effect of benzodiazepine hypnotics on all-night sleep EEG spectra","volume":"4","author":"Borbely","year":"1985","journal-title":"Hum Neurobiol"},{"key":"key\n\t\t\t\t2018112203580424800_B31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0006-8993(93)90579-C","article-title":"Dynamics of electroencephalographic sleep spindles and slow wave activity in men: effect of sleep deprivation","volume":"626","author":"Dijk","year":"1993","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t2018112203580424800_B32","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-0318-1","article-title":"Mixed-effects models in S and S-PLUS","author":"Pinheiro","year":"2000"},{"key":"key\n\t\t\t\t2018112203580424800_B33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/1469-8986.3820232","article-title":"The effects of age and gender on sleep EEG power spectral density in the middle years of life (ages 20-60 years old)","volume":"38","author":"Carrier","year":"2001","journal-title":"Psychophysiology"},{"key":"key\n\t\t\t\t2018112203580424800_B34","first-page":"113","article-title":"A practical guide to splines","author":"de Boor","year":"1978"},{"key":"key\n\t\t\t\t2018112203580424800_B35","article-title":"A natural approach for addressing multiplicity involving neuroscience functional data","volume-title":"JSM Proceedings, Biopharmaceutical Section","author":"Ma","year":"2011"},{"key":"key\n\t\t\t\t2018112203580424800_B36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/14656566.2012.667074","article-title":"Zolpidem for insomnia","volume":"13","author":"Greenblatt","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2018112203580424800_B37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2005-873160","article-title":"Low-dose trazodone effective in insomnia","volume":"38","author":"Bon","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"key\n\t\t\t\t2018112203580424800_B38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2869.2011.00928.x","article-title":"Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs","volume":"20","author":"Roth","year":"2011","journal-title":"J Sleep Res"},{"key":"key\n\t\t\t\t2018112203580424800_B39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.pharmthera.2005.04.014","article-title":"Treating insomnia: Current and investigational pharmacological approaches","volume":"112","author":"Ebert","year":"2006","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2018112203580424800_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02244546","article-title":"Effect of zolpidem on sleep and sleep EEG spectra in healthy young men","volume":"104","author":"Brunner","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2018112203580424800_B41","first-page":"1","article-title":"Chronic insomnia: clinical and research challenges--an agenda","volume":"44","author":"Riemann","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"key\n\t\t\t\t2018112203580424800_B42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.biopsycho.2012.08.009","article-title":"Increased EEG sigma and beta power during NREM sleep in primary insomnia","volume":"91","author":"Spiegelhalder","year":"2012","journal-title":"Biol Psychol"},{"key":"key\n\t\t\t\t2018112203580424800_B43","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/sleep\/31.12.1673","article-title":"EEG spectral analysis in primary insomnia: NREM period effects and sex differences","volume":"31","author":"Buysse","year":"2008","journal-title":"Sleep"},{"key":"key\n\t\t\t\t2018112203580424800_B44","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.sleep.2013.11.680","article-title":"Comparison of EEG power spectra between patients with primary insomnia and good sleeper controls, accounting for the effects of age, gender, and sleep period, using a large compilation of PSG recordings from three clinical trials","volume":"14S","author":"Svetnik","year":"2013","journal-title":"Sleep Medicine"},{"key":"key\n\t\t\t\t2018112203580424800_B45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jsmc.2010.08.002","article-title":"Drug-related sleep stage changes: functional significance and clinical relevance","volume":"5","author":"Roehrs","year":"2010","journal-title":"Sleep Med Clin"},{"key":"key\n\t\t\t\t2018112203580424800_B46","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/npp.2013.139","article-title":"Quantitative electroencephalography within sleep\/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats","volume":"38","author":"Fox","year":"2013","journal-title":"Neuropsychopharmacology"}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/37\/10\/1609\/26669002\/aasm.37.10.1609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T05:45:07Z","timestamp":1598334307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/37\/10\/1609\/2416783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.5665\/sleep.4068","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,10,1]]}}}